Estramustine phosphate in the treatment of advanced prostatic cancer.
Thirty patients with advanced carcinoma of the prostate were treated with estramustine phosphate. All patients were followed up for a minimum of 9 months. Of 15 not previously treated with oestrogens 9 responded objectively and 11 subjectively. Of 15 patients whose tumours had failed to respond to at least 2 oestrogens, 3 responded objectively and 5 subjectively. Adverse effects consisted of cardiovascular complications, gynaecomastia and impotence. Gastrointestinal side effects were minimal and no hepatic, renal or marrow toxicity was seen. The criteria of assessment of response are discussed.
D004961:Estramustine / Q000009:adverse effects / Q000627:therapeutic use*; D004967:Estrogens / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013997:Time Factors
D004967:Estrogens; D009588:Nitrogen Mustard Compounds; D004961:Estramustine